photonamic GmbH & Co. KG

What photonamic GmbH & Co. KG does

Photonamic GmbH & Co. KG is a privately held German specialty pharmaceutical company founded in 2002 and headquartered in Pinneberg, Germany, focused exclusively on the research, development, and commercialization of 5-aminolevulinic acid (5-ALA) and its derivatives. The company's commercial portfolio consists of two products: Gliolan® (oral 5-ALA HCl), used as an intraoperative imaging agent for fluorescence-guided resection of high-grade glioma and, pending supplemental FDA review, meningioma; and Alacare®, a topical 5-ALA formulation for photodynamic therapy (PDT) of actinic keratosis. The underlying mechanism exploits 5-ALA's selective metabolism to protoporphyrin IX (PPIX) in tumor or dysplastic cells, which fluoresces red-pink under 408 nm blue light and generates cytotoxic singlet oxygen under 635 nm red light, enabling both diagnostic visualization and therapeutic applications from a single molecular platform.

The company's pipeline extends the 5-ALA platform into ovarian cancer (EU and FDA Orphan Drug Designations), meningioma (MEN-301 Phase 3 positive), breast cancer, and non-small cell lung cancer (in collaboration with Lumeda). Photonamic operates a GMP-certified manufacturing facility at its Pinneberg site (licensed March 2024) and generates revenue through a mix of product supply, licensing/royalty arrangements with regional partners (NX Development Corp in the US, Medexus in Canada, SBI Pharmaceuticals in Asia), and contract manufacturing services. End customers are institutional — neurosurgery, neuro-oncology, dermatology, and gynecologic oncology departments — and products reach them through specialized channel partners rather than direct sales. The company is managed by Dr. Ulrich Kosciessa as Geschäftsführer (Managing Director) of the general partner Photonamic Verwaltungs-GmbH and has executed strategic acquisitions of NX Development Corp (2018), MolecuLight (2019), and a majority stake in FerroSens (2021) to broaden its technology and distribution footprint.

Name

photonamic GmbH & Co. KG

Legal name

Photonamic GmbH & Co. KG

Website

https://photonamic.de

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Photonamic GmbH & Co. KG is a privately held German specialty pharmaceutical company that develops and commercializes 5-aminolevulinic acid (5-ALA) based products for fluorescence-guided surgery and photodynamic therapy, serving neurosurgery, neuro-oncology, dermatology, and gynecologic oncology institutions globally through licensing partners.

Ownership category

akta.pro rank

Headquarters

HQ city

Wedel

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical product sales (Gliolan): Sale of Gliolan (5-ALA HCl) as a prescription pharmaceutical for fluorescence-guided surgery in high-grade glioma and meningioma. Distributed via licensing partners in international markets (e.g., NX Development Corp in the US, Medexus in Canada). Revenue generated through product supply to institutional/hospital customers.
2. Pharmaceutical product sales (Alacare): Sale of Alacare (topical 5-ALA formulation) for photodynamic therapy of actinic keratosis. Distributed through institutional and retail pharmacy channels. Revenue generated through product supply.
3. Licensing and royalties: Photonamic licenses its 5-ALA technology and product rights to commercial partners in various territories, generating upfront, milestone, and royalty revenues. Partners include SBI Pharmaceuticals, NX Development Corp, and Medexus.
4. Contract manufacturing under GMP: Photonamic operates GMP-certified manufacturing facilities and provides contract manufacturing services, generating revenue from pharmaceutical production for partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

photonamic develops, manufactures, and commercializes pharmaceutical products based on 5-aminolevulinic acid (5-ALA). Its two commercial products are Gliolan® (aminolevulinic acid HCl) used as an intraoperative imaging agent for fluorescence-guided resection of high-grade gliomas, and Alacare®, a topical 5-ALA patch used for photodynamic therapy (PDT) of actinic keratosis. The company also pursues GMP contract manufacturing and out-licenses its 5-ALA platform to commercial partners across multiple territories and indications.

Product overview

Photonamic GmbH & Co. KG is a pharmaceutical company focused on the development and commercialization of 5-aminolevulinic acid (5-ALA) based products for photodynamic therapy and fluorescence-guided surgery. The company operates two main commercial products: Gliolan® for intraoperative imaging in brain tumor (glioblastoma) surgery, and Alacare® for photodynamic treatment of actinic keratosis. Both products leverage the same core technology platform — 5-ALA, a photosensitizer precursor that selectively accumulates in tumor or abnormal cells and produces fluorescent signals or phototoxic effects when exposed to light of specific wavelengths.

Differentiator

Problem solved

Functional benefit

Brands

• Gliolan: Product for fluorescence-guided surgery in high-grade glioma. Contains aminolevulinic acid HCl for visualization of malignant tissue during neurosurgery.
• Alacare

Products and services

• Gliolan® Prescription pharmaceutical (aminolevulinic acid HCl) administered orally before neurosurgery to enable intraoperative fluorescence visualization of malignant tissue in patients with high-grade glioma (glioblastoma) and meningioma. Sold to hospitals and neurosurgery departments and distributed through licensing partners such as NX Development Corp (US) and Medexus (Canada).
• Alacare® Topical 5-aminolevulinic acid patch used in photodynamic therapy for the treatment of actinic keratosis (precancerous skin lesions). Applied by dermatologists and supplied through institutional and retail pharmacy channels.
• GMP Contract Manufacturing Services Contract pharmaceutical manufacturing services provided from photonamic's GMP-certified Pinneberg facility, offered to commercial partners needing production of 5-ALA-based or related pharmaceutical products.
• 5-ALA Licensing and Royalty Rights Licensing of 5-aminolevulinic acid technology, product rights, and regulatory data to pharmaceutical partners (e.g., NX Development Corp, Medexus, SBI Pharmaceuticals) for development and commercialization in specific geographies and indications.

Quantifiable outcome

• Phase 3 MEN-301 study met primary endpoint for 5-ALA in meningioma surgery (April 2025)
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Photonics HealthcarecoreStrategic or Co-development Partner · 12 April 2023Photonamic and Photonics Healthcare entered a joint collaboration to strengthen their partnership following a successful clinical pilot study of oxygen measurement technology. The collaboration aims to advance photodynamic therapy applications through integrated technology development.
• LumedacoreStrategic or Co-development Partner · 16 February 2023Photonamic and Lumeda entered a collaboration for a clinical study applying photodynamic therapy (PDT) with 5-aminolevulinic acid in the field of non-small cell lung cancer (NSCLC). The partnership combines Photonamic's 5-ALA platform with Lumeda's technology for PDT treatment in lung cancer.
• FerroSenscoreStrategic or Co-development Partner · 16 April 2021Photonamic acquired a majority stake in FerroSens, expanding its portfolio of technologies. FerroSens developed FIDscreen prototype devices which were successfully applied in a clinical study during blood donation. The acquisition broadens Photonamic's reach into diagnostics.
• SBI Pharmaceuticals Co., Ltd.coreStrategic or Co-development Partner · 8 March 2021Photonamic and SBI Pharmaceuticals collaborated on a Phase II clinical trial using 5-ALA, conducted by the University of Oxford and SBI Pharmaceuticals. The partnership leverages SBI Pharmaceuticals' regulatory and commercial capabilities alongside Photonamic's 5-ALA technology for clinical development.
• University of OxfordcoreStrategic or Co-development PartnerUniversity of Oxford collaborated with SBI Pharmaceuticals on a Phase II clinical trial using 5-ALA. The academic partnership provides clinical research capabilities and clinical site infrastructure for evaluating 5-ALA in new therapeutic applications.
• NX Development CorpcoreChannel Partner/ Reseller/ DistributorNX Development Corp (NXDC) holds US commercial rights to Gleolan (aminolevulinic acid HCl) and is conducting the MEN-301 Phase 3 clinical trial in meningioma. NXDC submitted supplemental data to FDA in April 2026 as an efficacy supplement to the existing Gleolan NDA. The relationship is a licensing/distribution arrangement for the US market.
• MedexuscoreChannel Partner/ Reseller/ DistributorMedexus handles the commercialization and distribution of Gleolan in Canada, having announced expanded availability of the product in Canada.
• SBI ALApromo GmbHminorChannel Partner/ Reseller/ DistributorSBI ALApromo GmbH registered a 5-aminolevulinic acid phosphate-containing cosmetic product (Kiyomi Skin) in Saudi Arabia, extending Photonamic's 5-ALA technology into the cosmetics and consumer health segment in the Middle East.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Photocure ASA: Photocure commercializes Hexvix/Lumacan, also a 5-aminolevulinic acid-based fluorescence imaging agent for bladder cancer. Photonamic and Photocure share the same 5-ALA photosensitizer mechanism, fluorescence-guided surgery application, and specialty pharma go-to-market model.
• SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals is the Japanese 5-ALA developer and Photonamic's long-standing collaboration partner. SBI develops the same 5-ALA molecule across multiple indications including dermatology and oncology, making it the closest direct peer in the 5-ALA platform space.
• NX Development Corp: NX Development Corp holds US commercial rights to Gleolan and runs the MEN-301 Phase 3 meningioma trial. It functions as both a commercial partner and a parallel developer of 5-ALA fluorescence-guided surgery in the US market.
• biolitec AG: biolitec is a medical technology company specializing in photodynamic therapy for oncology and other indications, with both laser light sources and photosensitizer products. Comparable to Photonamic's Alacare PDT franchise and complementary device offerings.

Emerging players

• Lumeda: Lumeda collaborates with Photonamic on a clinical study applying 5-ALA-based photodynamic therapy in non-small cell lung cancer. It is an emerging PDT device/technology player operating in the same photodynamic oncology space.
• Photonics Healthcare: Photonics Healthcare partners with Photonamic on oxygen measurement technology integration with photodynamic therapy. Comparable as a PDT-enabling technology developer in the same ecosystem.

Broad incumbents

• Stryker (Novadaq): Stryker acquired Novadaq Technologies, which commercializes SPY fluorescence imaging for intraoperative visualization. As a broad incumbent in surgical imaging, it competes with Photonamic's fluorescence-guided surgery platform on the device/imaging side.
• Karl Storz SE & Co. KG: Karl Storz is a major endoscopy and surgical visualization company with fluorescence imaging capabilities used alongside 5-ALA in fluorescence-guided neurosurgery. Relevant as the broader surgical imaging incumbent ecosystem in which Photonamic's Gliolan is used.
• Hamamatsu Photonics K.K. Hamamatsu supplies light sources, sensors, and cameras used in photodynamic therapy and intraoperative fluorescence imaging. Comparable as a broader incumbent enabling Photonamic's photodynamic applications.

Regional players

• Medexus Pharmaceuticals: Medexus handles Canadian distribution of Gleolan for Photonamic and operates as a regional specialty pharma distributor. Comparable as a regional commercialization partner in the 5-ALA fluorescence-guided surgery market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about photonamic GmbH & Co. KG